• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

开发适用于阿尔茨海默病患者认知-交流障碍的移动兼容软件。

Development of mobile compatible software for cognitive-communication disorder in individuals with Alzheimer's disease.

机构信息

Department of Speech and Language Therapy, Faculty of Health Sciences, Ankara Yıldırım Beyazıt University, Ankara, Turkey.

Department of Speech and Language Therapy, Faculty of Health Sciences, Hacettepe University, Ankara, Turkey.

出版信息

Int J Lang Commun Disord. 2024 Jan-Feb;59(1):234-254. doi: 10.1111/1460-6984.12941. Epub 2023 Aug 1.

DOI:10.1111/1460-6984.12941
PMID:37528064
Abstract

BACKGROUND

Alzheimer's disease (AD) is a progressive neurodegenerative disease. Cognitive functions and communication skills worsen as the disease progresses, thereby reducing patients' independence levels. Therefore, recommending software that can be used at home may be a useful means of slowing down the cognitive and communicative decline in AD.

AIMS

To develop software that can be used at home to slow down the cognitive and communicative decline and increase independence in individuals with AD; and to examine the effect of this software on the cognitive communication skills of individuals with AD.

METHODS & PROCEDURES: The study was completed in four stages: the development of the application; the evaluation of the participants and their training for the application; their use of the application at home; and the re-evaluation of the participants. A total of 32 individuals who met the inclusion criteria were included in the study. These individuals were randomly divided into study and control groups, each consisting of a total of 16 participants, including six in the mild stage, six in the moderate stage, and four in the severe stages. The developed software was loaded on tablets and given to the participants in the study group. The participants in the control group only received their pharmacological treatment, while those in the study group received both their pharmacological treatment and used the developed application. All participants were evaluated with the Mini-Mental State Examination (MMSE) and Language Assessment Test for Aphasia (LATA) before and after application use. A survey was administered to the caregivers of the participants in the study group after the use of the application.

OUTCOMES & RESULTS: The results revealed a positive change in the cognitive-communication skills of the individuals in the study group, even if they were in the severe stage, according to the LATA and MMSE, as well as the survey. The application led to the greatest improvements in grammar on the LATA and orientation on the MMSE. No rapid cognitive decline was seen in individuals at all stages in the control group.

CONCLUSIONS & IMPLICATIONS: In this study, software was developed in Turkish that can be used in every stage of AD as part of a holistic cognitive-communication intervention programme offering alternative and supportive communication for individuals with AD, even those in the severe stage. Results prove the effectiveness of the developed software on the cognitive-communication skills of individuals with AD.

WHAT THIS PAPER ADDS

What is already known on the subject There are a few (as far as is known, three) applications developed in English for cognitive-communication disorders due to dementia. What this study adds to the existing literature In this study, for the first time in Turkish, mobile-compatible software has been developed for both cognitive and communication disorders that is specific to individuals with AD and can be used by individuals at all stages of the disease. The effects of the application we developed on the cognitive-communication skills of individuals with AD were shown in a randomised controlled trial. What are the potential or actual clinical implications of this work? Using the app can help people with all stages of AD keep their cognitive and communication skills and have a better prognosis in terms of cognitive-communication skills, especially grammar and orientation.

摘要

背景

阿尔茨海默病(AD)是一种进行性神经退行性疾病。随着疾病的发展,认知功能和沟通技巧会恶化,从而降低患者的独立性水平。因此,推荐可以在家中使用的软件可能是减缓 AD 患者认知和沟通能力下降的一种有用手段。

目的

开发可以在家中使用的软件,以减缓认知和沟通能力下降,提高 AD 患者的独立性;并研究该软件对 AD 患者认知沟通能力的影响。

方法和程序

研究分四个阶段完成:应用程序的开发;参与者评估及其对应用程序的培训;在家中使用该应用程序;以及参与者的重新评估。共有 32 名符合纳入标准的个体参与了研究。这些个体被随机分为研究组和对照组,每组各有 16 名参与者,包括轻度阶段 6 名,中度阶段 6 名,重度阶段 4 名。开发的软件被加载到平板电脑上,并分发给研究组的参与者。对照组的参与者仅接受药物治疗,而研究组的参与者则同时接受药物治疗和使用开发的应用程序。所有参与者在使用应用程序前后均使用简易精神状态检查(MMSE)和失语症语言评估测试(LATA)进行评估。研究组参与者的护理人员在使用应用程序后进行了问卷调查。

结果和结论

根据 LATA 和 MMSE,以及调查结果,研究组的参与者的认知沟通能力发生了积极变化,即使他们处于重度阶段。该应用程序在 LATA 上的语法和 MMSE 上的定向方面带来了最大的改善。对照组中所有阶段的个体都没有出现快速的认知下降。

在这项研究中,我们开发了一种土耳其语的软件,可以作为整体认知沟通干预计划的一部分,为 AD 患者提供替代和支持性的沟通,即使是处于重度阶段的患者。研究结果证明了开发的软件对 AD 患者认知沟通能力的有效性。

已知的该主题相关内容

目前已有一些(据所知,三个)英语开发的应用程序用于治疗痴呆引起的认知沟通障碍。

本研究的创新之处

在土耳其语中,我们首次开发了一种针对 AD 患者的认知和沟通障碍的移动兼容软件,适用于疾病各个阶段的患者。我们在随机对照试验中展示了我们开发的应用程序对 AD 患者认知沟通能力的影响。

这项工作的潜在或实际临床意义是什么?使用该应用程序可以帮助各个阶段的 AD 患者保持他们的认知和沟通能力,并在认知沟通技能方面有更好的预后,特别是语法和定向能力。

相似文献

1
Development of mobile compatible software for cognitive-communication disorder in individuals with Alzheimer's disease.开发适用于阿尔茨海默病患者认知-交流障碍的移动兼容软件。
Int J Lang Commun Disord. 2024 Jan-Feb;59(1):234-254. doi: 10.1111/1460-6984.12941. Epub 2023 Aug 1.
2
Donepezil for dementia due to Alzheimer's disease.多奈哌齐用于治疗阿尔茨海默病所致的痴呆。
Cochrane Database Syst Rev. 2018 Jun 18;6(6):CD001190. doi: 10.1002/14651858.CD001190.pub3.
3
Pharmacotherapies for sleep disturbances in dementia.痴呆症睡眠障碍的药物治疗
Cochrane Database Syst Rev. 2016 Nov 16;11(11):CD009178. doi: 10.1002/14651858.CD009178.pub3.
4
The Black Book of Psychotropic Dosing and Monitoring.《精神药物剂量与监测黑皮书》
Psychopharmacol Bull. 2024 Jul 8;54(3):8-59.
5
Pharmacotherapies for sleep disturbances in Alzheimer's disease.用于治疗阿尔茨海默病睡眠障碍的药物疗法。
Cochrane Database Syst Rev. 2014 Mar 21(3):CD009178. doi: 10.1002/14651858.CD009178.pub2.
6
Reminiscence therapy for dementia.痴呆症的回忆疗法
Cochrane Database Syst Rev. 2018 Mar 1;3(3):CD001120. doi: 10.1002/14651858.CD001120.pub3.
7
Plasma and cerebrospinal fluid amyloid beta for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).血浆和脑脊液β淀粉样蛋白用于诊断轻度认知障碍(MCI)患者的阿尔茨海默病性痴呆及其他痴呆。
Cochrane Database Syst Rev. 2014 Jun 10;2014(6):CD008782. doi: 10.1002/14651858.CD008782.pub4.
8
Positive effects of speech and language therapy group interventions in primary progressive aphasia: A systematic review.言语语言治疗小组干预对原发性进行性失语症的积极影响:系统评价。
Int J Lang Commun Disord. 2024 Sep-Oct;59(5):1832-1849. doi: 10.1111/1460-6984.13031. Epub 2024 Apr 11.
9
Evaluating structure and content of parent-implemented early logopaedic intervention models following the three stages of communicative development in children with cleft lip and/or palate: Systematic literature review with narrative synthesis.评估唇腭裂儿童沟通发展三阶段中父母实施早期言语治疗干预模式的结构和内容:系统文献回顾与叙述性综合。
Int J Lang Commun Disord. 2024 Sep-Oct;59(5):1923-1945. doi: 10.1111/1460-6984.13038. Epub 2024 May 10.
10
Efficacy of nicergoline in dementia and other age associated forms of cognitive impairment.尼麦角林治疗痴呆及其他与年龄相关的认知障碍形式的疗效。
Cochrane Database Syst Rev. 2001;2001(4):CD003159. doi: 10.1002/14651858.CD003159.

引用本文的文献

1
Language and Communication Interventions in People with Alzheimer's Disease: A Systematic Review.阿尔茨海默病患者的语言与沟通干预:一项系统综述。
Healthcare (Basel). 2024 Mar 29;12(7):741. doi: 10.3390/healthcare12070741.
2
Voice analysis results in individuals with Alzheimer's disease: How do age and cognitive status affect voice parameters?阿尔茨海默病患者的语音分析结果:年龄和认知状态如何影响语音参数?
Brain Behav. 2023 Nov;13(11):e3271. doi: 10.1002/brb3.3271. Epub 2023 Oct 4.
3
Validity and reliability of the Turkish version of the Holden Communication Scale.
《 Holden 沟通量表土耳其文版的有效性和信度》。
Brain Behav. 2023 Sep;13(9):e3223. doi: 10.1002/brb3.3223. Epub 2023 Aug 17.